ArticleInternational journal of molecular sciences2026
Integrating Molecular and Imaging Insights: Ryanodine Receptor 2 (RyR2) Expression, CK18 Status, and Conventional MRI Findings in Pituitary Neuroendocrine Tumors.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Ryanodine receptor 2 (RyR2) has been increasingly recognized as an important regulator in cancer biology. Previous studies demonstrate that RyR2 expression is associated with patient survival, although its precise role in tumorigenesis remains unclear. Elevated RyR2 expression has been linked to poorer survival outcomes, while gene silencing or pharmacological inhibition (e.g., with S107) has been shown to reduce cancer cell metastasis in both in vitro and in vivo models. Cytokeratin 18 (CK18), a key epithelial marker, is associated with tumor differentiation, hormonal phenotype, and clinical behavior in pituitary neuroendocrine tumors (PitNETs), reflecting underlying cytoskeletal organization. Variations in CK18 expression have been linked to distinct adenoma subtypes and may provide insight into tumor aggressiveness. This exploratory study investigated associations between RyR2 expression, CK18 status, and conventional MRI findings of pituitary tumors. Quantitative T2-weighted signal intensity and radiomic features were not assessed. This exploratory observational study used prospective patient recruitment between January 2017 and January 2026, after ethics approval was obtained in December 2016. RyR2 expression in immunohistological samples was quantified using QuPath v0.6.0. CK18 immunostaining was performed with the Dako Omnis system according to the manufacturer's protocols. Conventional MRI findings were available for 24 patients and were retrospectively reviewed. Statistical analysis was conducted using SPSS/W 31.0. No statistically significant associations were observed between RyR2 expression and sex, hormonal activity, tumor size, invasiveness, recurrence, or the evaluated conventional MRI findings (all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.